Owkin exists to find the right treatment for every patient.

Our vision

To find better treatments, everything starts with a “why?”

Why do some cancer patients respond well to some drugs while others don’t? Work with us to find the answers across four focus areas.

Work with us to find the answers across four focus areas.

Circle image
Circle arrow
Mobile Line

Owkin’s platform

Owkin’s platform

Desktop line

Our platform consists of three capabilities.

Circle image

01. Data access & federated learning

We access data at scale with federated learning to preserve patient privacy and data security

03. Interpretable AI

We create interpretable AI to answer a broad range of research questions

02. Expertise in biology & medicine

We combine insights from world class experts in cancer with our in-house biological knowledge to make sense of multimodal datasets

02. Expertise in biology & medicine

We combine insights from world class experts in cancer with our in-house biological knowledge to make sense of multimodal datasets

03. Interpretable AI

We create interpretable AI to answer a broad range of research questions

We use this platform for internal R&D and make it available to partners to accelerate discovery and development projects.

Why Owkin?

150 & 30

Team of 150 (30 PhDs)

55

55 research organizations and hospitals in our network

25

25 publications in top-tier scientific journals

160 & 44

160 KOLs of which 44 have a H-index above 40

8

8 consortia with top pharma and research centers

18 & 8

18 cancers investigated with a focus on 8

200,000

Multimodal and longitudinal datasets with 200,000 patients across cohorts

ISO27001

Secure, robust and audited technology that works on traceable infrastructure. GDPR compliant

150 & 30

Team of 150 (30 PhDs)

55

55 research organizations and hospitals in our network

25

25 publications in top-tier scientific journals

160 & 44

160 KOLs of which 44 have a H-index above 40

8

8 consortia with top pharma and research centers

18 & 8

18 cancers investigated with a focus on 8

200,000

Multimodal and longitudinal datasets with 200,000 patients across cohorts

ISO27001

Secure, robust and audited technology that works on traceable infrastructure. GDPR compliant

Join the conversation

arrow-desktop

Join the conversation

arrow-mobile
Owkin sphere on blue background

Owkin and CancerLinQ collaborate to use federated learning on real-world oncology data in a study to understand lung cancer treatment

Read more

Visit our booth 2F35 at ECP2022 in Basel (Sept 3-7th, 2022) for a demo of our diagnostic solutions.

Set up a meeting with us

Visit us at ESMO Congress 2022, booth 252a, to learn about our latest diagnostics and what we are doing at the intersection of spatial omics and artificial intelligence to enable the next revolution in oncology research.

Contact us for a meeting
working in nantes

A place for people who ask “why?” Explore our open positions and apply today.

Apply here

Hear from our partners

01/03

background-shapes

“Owkin’s unique methodology, which applies AI to patient data from partnerships with multiple academic medical centres, supports our ambition to leverage data in innovative ways in R&D. We are striving to advance precision medicine and to discover innovative treatment methods with the greatest benefits for patients.”

Arnaud Robert

Executive Vice President, Chief Digital Officer, Sanofi

Arnaud Robert

“Owkin combines the power of trials, labs and data science to converge towards the delivery of personalized value-based medicine. Thanks to Owkin's sophisticated computation and inference, together we have generated insights, enabling us to reason and learn, to empower our decision making.”

Professor Shahrokh Shariat

Chair of Urology at the Medical University of Vienna

Professor Shahrokh Shariat

“Without federated learning, most biomedical data would likely remain unused and unavailable to construct the next generation of predictive algorithms.”

Olivier Elemento

Director of Caryl and Israel Englander Institute for Precision Medicine at Cornell University

Olivier Elemento